Screener
BridgeBio Pharma BBIO Repayments of deferred royalty obligations
Repayments of deferred royalty obligations at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept bbio:PaymentOfDeferredRoyaltyObligation.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
FAQ
- What is BridgeBio Pharma's repayments of deferred royalty obligations?
- BridgeBio Pharma (BBIO) reported repayments of deferred royalty obligations of $11.29M in Q1 2026.
- How has BridgeBio Pharma's repayments of deferred royalty obligations changed year-over-year?
- BridgeBio Pharma's repayments of deferred royalty obligations increased by 7742.4% year-over-year, from $144K to $11.29M.
- What does repayments of deferred royalty obligations mean?
- Cash payments made to settle liabilities related to future royalty streams that were previously monetized or deferred. This represents the fulfillment of contractual obligations tied to specific product revenue or intellectual property rights.
Ask your AI about BridgeBio Pharma's repayments of deferred royalty obligations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude